Short answer
Lyell Immunopharma Inc (LYEL) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $3,000 (down 80.0% year over year) with net income of −$46M.
Q3 2026 key financials · XBRL
- Revenue
- $3,000
- −80.0% YoY · −25.0% QoQ
- Net income
- −$46M
- −17.2% YoY · −1.7% QoQ
- Operating margin
- -1609833.3%
- EPS (diluted)
- −$1.88
- +4.1% YoY · +3.6% QoQ
Source: XBRL data from the Lyell Immunopharma Inc (LYEL) Q3 2026 10-Q on SEC EDGAR. USD.
Lyell Immunopharma Inc Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY, no approved products or product sales
- Operating loss $48.3M vs $37.3M YoY, net loss $45.5M vs $38.8M
- R&D expense $40.9M vs $28.2M, driven by increased clinical trial activity
- Cash, equivalents and marketable securities $194.0M; operating cash outflow $107.0M
- Guidance: liquidity sufficient for at least 12 months; additional capital needed, with clinical and manufacturing costs rising
Risk Factors
- Newly added trade-policy risk: April 2026 tariffs up to 100% on certain imported pharmaceuticals, APIs and key starting materials
- Most materially updated capital risk: November 2026 Securities Purchase Agreement is the only committed external funding source
- Regulatory compliance risk: cGMP or cGTP failures could trigger clinical holds, production suspension, recalls or approval withdrawal
- Near-term trial risk: Competitor liso-cel and axi-cel availability may reduce enrollment in the PiNACLE-H2H trial
- Financial dilution risk: ICT may receive up to 1.85 million additional shares, including 1.1 million issued in July 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.